Zhengye Biotechnology (ZYBT) Income Statement (2022 - 2025)
Annual Income Statement report data from Dec 31, 2022 to Dec 31, 2025 for Zhengye Biotechnology (ZYBT) in CNY with ability to convert in USD.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
Revenue and COGS | ||||
Total Revenue | 116M (-37.56%) | 186M (-11.95%) | 212M (-18.68%) | 260M |
Cost Of Revenue | 92M (-2.70%) | 95M (+0.98%) | 94M (-16.24%) | 112M |
Costof Goods And Services Sold | 92M (-2.70%) | 95M (+0.98%) | 94M (-16.24%) | 112M |
Gross Profit | 24M (-73.86%) | 91M (-22.30%) | 118M (-20.54%) | 148M |
Operating Expenses | ||||
Research And Development | 18M (+40.81%) | 13M (+7.48%) | 12M (-11.33%) | 13M |
Selling General And Administrative | 31M (+37.33%) | 23M (-4.28%) | 24M (-3.00%) | 24M |
Operating Expenses | 94M (+26.08%) | 75M (+3.23%) | 73M (-11.61%) | 82M |
Depreciation And Amortization | 26M (+7.12%) | 24M (+1.05%) | 24M (+27.18%) | 19M |
Operating Income | ||||
Operating Income | -70.51M | 16M (-63.46%) | 45M (-31.66%) | 66M |
Ebit | -70.51M | 16M (-63.46%) | 45M (-31.66%) | 66M |
EBITDA | -44.62M | 41M (-41.07%) | 69M (-18.59%) | 85M |
Other Income / Expenses | ||||
Interest Income | 100K (-56.52%) | 230K (-25.81%) | 310K (+181.82%) | 110K |
Interest Expense | 3.40M (-15.84%) | 4.04M (-8.60%) | 4.42M (+55.63%) | 2.84M |
Net Interest Income | 100K (-56.52%) | 230K (-25.81%) | 310K (+181.82%) | 110K |
Other Non Operating Income | -130.00K | 150K (-34.78%) | 230K | -1.92M |
Net Income | ||||
Income Before Tax | -71.87M | 14M (-67.12%) | 44M (-31.53%) | 64M |
Income Tax Expense | 11M (+1106.52%) | 920K (-85.28%) | 6.25M (-23.50%) | 8.17M |
Net Income From Continuing Operations | -69.78M | 11M (-64.05%) | 31M (-32.69%) | 47M |
Net Income | -69.78M | 11M (-64.05%) | 31M (-32.69%) | 47M |
Comprehensive Income Net Of Tax | -71.71M | 11M (-64.05%) | 31M (-32.69%) | 47M |